Skip to main content
main-content

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

01.02.2017 | short review | Ausgabe 1/2017

memo - Magazine of European Medical Oncology 1/2017

Milestones in myeloma

Zeitschrift:
memo - Magazine of European Medical Oncology > Ausgabe 1/2017
Autor:
Niklas Zojer

Summary

The field of myeloma has been very dynamic in the last 10 years. Indeed, in no other hematological malignancy has progress been so rapid. In Europe, five new myeloma drugs were approved in the 2‑year period during 2015–2016. This has already had a profound impact on the way we approach treatment of relapsed disease. In the near future, the results of trials evaluating some of these very new substances in first-line treatment will be available and hopefully will show a further improvement of disease control over what has already been achieved with current upfront protocols.

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Literatur
Über diesen Artikel

Weitere Artikel der Ausgabe 1/2017

memo - Magazine of European Medical Oncology 1/2017 Zur Ausgabe